Irreversible blockade of sigma-1 receptors by haloperidol and its metabolites in guinea pig brain and SH-SY5Y human neuroblastoma cells

Journal of Neurochemistry

Volumn 102, Issue 3, 2007, Pages 812-825

  Cobos, Enrique J ^a   Pozo, Esperanza Del ^a   Baeyens, José M ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

Author keywords

3H (+) pentazocine binding; Guinea pig brain; Haloperidol metabolism; Receptor turnover; SH SY5Y human neuroblastoma cells; Sigma 1 receptors

Indexed keywords

2 [4 METHOXY 3 (2 PHENYLETHOXY)PHENYL] N,N DIPROPYLETHYLAMINE; HALOPERIDOL; OPIATE ANTAGONIST; PENTAZOCINE; SIGMA 1 OPIATE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; CELL STRAIN; CONTROLLED STUDY; GUINEA PIG; HUMAN; HUMAN CELL; MALE; NERVE CELL CULTURE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; RECEPTOR DENSITY; RECEPTOR INTRINSIC ACTIVITY; RECEPTOR SENSITIVITY; STEADY STATE;

ANIMALS; BINDING, COMPETITIVE; BRAIN; CELL LINE, TUMOR; DOPAMINE ANTAGONISTS; GUINEA PIGS; HALOPERIDOL; HUMANS; MALE; MOLECULAR STRUCTURE; NARCOTIC ANTAGONISTS; NEURONS; PENTAZOCINE; RADIOLIGAND ASSAY; RECEPTOR AGGREGATION; RECEPTORS, SIGMA; SUBCELLULAR FRACTIONS;

CAVIA;

EID: 34447302551     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2007.04533.x     Document Type: Article

References (50)

1. Barturen F. Garcia-Sevilla J. A. (1992) Long term treatment with desipramine increases the turnover of α2-adrenoceptors in the rat brain. Mol. Pharmacol. 42, 846 855.
2. Battaglia G., Norman A. B. Creese I. (1987) Differential serotonin2 receptor recovery in mature and senescent rat brain after irreversible receptor modification: effect of chronic reserpine treatment. J. Pharmacol. Exp. Ther. 243, 69 75.
3. Bloomquist J., King E., Wright A., Mytilineou C., Kimura K., Castagnoli K. Castagnoli N. Jr. (1994) 1-Methyl-4-phenylpyridinium-like neurotoxicity of a pyridinium metabolite derived from haloperidol: cell culture and neurotransmitter uptake studies. J. Pharmacol. Exp. Ther. 270, 822 830.
4. Bluth L. S., Rice K. C., Jacobson A. E. Bowen W. D. (1989) Acylation of σ receptors by Metaphit, an isothiocyanate derivative of phencyclidine. Eur. J. Pharmacol. 161, 273 277.
5. Bowen W. D., Moses E. L., Tolentino P. J. Walker J. M. (1990) Metabolites of haloperidol display preferential activity at sigma receptors compared to dopamine D-2 receptors. Eur. J. Pharmacol. 177, 111 118.
6. Cendan C. M., Pujalte J. M., Portillo-Salido E., Montoliu L. Baeyens J. M. (2005a) Formalin-induced pain is reduced in σ1 receptor knockout mice. Eur. J. Pharmacol. 511, 73 74.
7. Cendan C. M., Pujalte J. M., Portillo-Salido E. Baeyens J. M. (2005b) Antinociceptive effects of haloperidol and its metabolites in the formalin test in mice. Psychopharmacology (Berl.) 182, 485 493.
8. Cobos E. J., Baeyens J. M. Del Pozo E. (2005) Phenytoin differentially modulates the affinity of agonist and antagonist ligands for σ1 receptors of guinea pig brain. Synapse 55, 192 195.
9. Cobos E. J., Lucena G., Baeyens J. M. Del Pozo E. (2006) Differences in the allosteric modulation by phenytoin of the binding properties of the σ1 ligands [3H](+)-pentazocine and [3H]NE-100. Synapse 59, 152 161.
10. DeHaven-Hudkins D. L., Lanyon L. F., Ford-Rice F. Y. Ator M. A. (1994) σ recognition sites in brain and peripheral tissues. Characterization and effects of cytochrome P450 inhibitors. Biochem. Pharmacol. 47, 1231 1239.
11. DeLean A., Munson P. J. Rodbard D. (1978) Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am. J. Physiol. 235, E97 E102.
12. Eyles D. W. Pond S. M. (1992) Stereospecific reduction of haloperidol in human tissues. Biochem. Pharmacol. 44, 867 871.
13. Eyles D. W., McGrath J. J. Pond S. M. (1996) Formation of pyridinium species of haloperidol in human liver and brain. Psychopharmacology (Berl.) 125, 214 219.
14. Fang J. Gorrod J. W. (1993) High-performance liquid chromatographic method for the detection and quantitation of haloperidol and seven of its metabolites in microsomal preparations. J. Chromatogr. 614, 267 273.
15. Fang J., Zuo D. Yu P. H. (1995) Comparison of cytotoxicity of a quaternary pyridinium metabolite of haloperidol (HP+) with neurotoxin N-methyl-4-phenylpyridinium (MPP+) towards cultured dopaminergic neuroblastoma cells. Psychopharmacology (Berl.) 121, 373 378.
16. Fang J., McKay G., Song J., Remillrd A., Li X. Midha K. (2001) In vitro characterization of the metabolism of haloperidol using recombinant cytochrome P450 enzymes and human liver microsomes. Drug Metab. Dispos. 29, 1638 1643.
17. Freedman S. B., Patel S., Marwood R., Emms F., Seabrook G. R., Knowles M. R. McAllister G. (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. J. Pharmacol. Exp. Ther. 268, 417 426.
18. Guitart X., Codony X. Monroy X. (2004) Sigma receptors: biology and therapeutic potential. Psychopharmacology (Berl.) 174, 301 319.
19. Gurd J. W., Jones L. R., Mahler H. R. Moore W. J. (1974) Isolation and partial characterization of rat brain synaptic plasma membranes. J. Neurochem. 22, 281 290.
20. Hanner M., Moebius F. F., Flandorfer A., Knaus H. G., Striessnig J., Kempner E. Glossmann H. (1996) Purification, molecular cloning, and expression of the mammalian sigma1-binding site. Proc. Natl Acad. Sci. USA 93, 8072 8077.
21. Hayashi T. Su T. P. (2004) σ-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 18, 269 284.
22. Hellewell S. B. Bowen W. D. (1990) A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain. Brain Res. 527, 244 253.
23. Hong W. Werling L. L. (2002) Binding of σ receptor ligands and their effects on muscarine-induced Ca2+ changes in SH-SY5Y cells. Eur. J. Pharmacol. 436, 35 45.
24. Hong W., Nuwayhid S. J. Werling L. L. (2004) Modulation of bradykinin-induced calcium changes in SH-SY5Y cells by neurosteroids and sigma receptor ligands via a shared mechanism. Synapse 54, 102 110.
25. Igarashi K., Kasuya F., Fukui M., Usuki E. Castagnoli N. Jr. (1995) Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP. Life Sci. 57, 2439 2446.
26. Inoue A., Miki S., Seto M., Kikuchi T., Morita S., Ueda H., Misu Y. Nakata Y. (1997) Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur. J. Pharmacol. 321, 105 111.
27. Inoue A., Sugita S., Shoji H., Ichimoto H., Hide I. Nakata Y. (2000) Repeated haloperidol treatment decreases σ1 receptor binding but does not affect its mRNA levels in the guinea pig or rat brain. Eur. J. Pharmacol. 401, 307 316.
28. Itzhak Y., Stein I., Zhang S. H., Kassim C. O. Cristante D. (1991) Binding of sigma-ligands to C57BL/6 mouse brain membranes: effects of monoamine oxidase inhibitors and subcellular distribution studies suggest the existence of sigma-receptor subtypes. J. Pharmacol. Exp. Ther. 257, 141 148.
29. Kekuda R., Prasad P. D., Fei Y. J., Leibach F. H. Ganapathy V. (1996) Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 229, 553 558.
30. Klein M., Cooper T. B. Musacchio J. M. (1994) Effects of haloperidol and reduced haloperidol on binding to σ sites. Eur. J. Pharmacol. 254, 239 248.
31. Korpi E. R., Costakos D. T. Wyatt R. J. (1985) Interconversions of haloperidol and reduced haloperidol in guinea pig and rat liver microsomes. Biochem. Pharmacol. 34, 2923 2927.
32. Lowry O.H., Rosenbrough N.J., Farr A.L. Randall R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265 275.
33. Marder S.R. (1998) Antipsychotic medications, in The American Psychiatric Press textbook of psychopharmacology, 2nd Edn Schatzberg A. F. Nemeroff C. H., eds pp. 309 321. American Psychiatric Press Inc, Washington.
34. Matsumoto R. R. Pouw B. (2000) Correlation between neuroleptic binding to σ1 and σ2 receptors and acute dystonic reactions. Eur. J. Pharmacol. 401, 155 160.
35. Matsumoto R. R., McCracken K. A., Friedman M. J., Pouw B., De Costa B. R. Bowen W. D. (2001) Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting σ1 receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 419, 163 174.
36. Maurice T., Martin-Fardon R., Romieu P. Matsumoto R. R. (2002) Sigma1 (σ1) receptor antagonists represent a new strategy against cocaine addiction and toxicity. Neurosci. Biobehav. Rev. 26, 499 527.
37. McCracken K. A., Bowen W. D., De Costa B. R. Matsumoto R. R. (1999) Two novel σ receptor ligands, BD1047 and LR172, attenuate cocaine-induced toxicity and locomotor activity. Eur. J. Pharmacol. 370, 225 232.
38. Nakazato A., Kumagai T., Ohta K., Chaki S., Okuyama S. Tomisawa K. (1999) Synthesis and SAR of 1-alkyl-2-phenylethylamine derivatives designed from N,N-dipropyl-4-methoxy-3-(2-phenylethoxy)phenylethylamine to discover σ1 ligands. J. Med. Chem. 42, 3965 3970.
39. Norman A. B., Battaglia G. Creese I. (1987) Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification: a key to receptor regulatory mechanisms. J. Neurosci. 7, 1484 1491.
40. Pan L. P., De Vriendt C. Belpaire F. M. (1998a) In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. Pharmacogenetics 8, 383 389.
41. Pan Y. X., Mei J., Xu J., Wan B. L., Zuckerman A. Pasternak G. W. (1998b) Cloning and characterization of a mouse σ1 receptor. J. Neurochem. 70, 2279 2285.
42. Park K. H., Lee M. H. Lee M. G. (1991) Simultaneous determination of haloperidol and its metabolite, reduced haloperidol, in plasma, blood, urine and tissue homogenates by high-performance liquid chromatography. J. Chromatogr. 572, 259 267.
43. Pineda J., Ruiz-Ortega J. A. Ugedo L. (1997) Receptor reserve and turnover of alpha-2 adrenoceptors that mediate the clonidine-induced inhibition of rat locus coeruleus neurons in vivo. J. Pharmacol. Exp. Ther. 281, 690 698.
44. Quirion R., Bowen W. D., Itzhak Y., Junien J. L., Musacchio J. M., Rothman R. B., Su T. P., Tam S. W. Taylor D. P. (1992) A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 13, 85 86.
45. Reynolds G. P., Brown J. E. Middlemiss D. N. (1991) [3H]ditolylguanidine binding to human brain σ sites is diminished after haloperidol treatment. Eur. J. Pharmacol. 194, 235 236.
46. Romieu P., Phan V. L., Martin-Fardon R. Maurice T. (2002) Involvement of the sigma1 receptor in cocaine-induced conditioned place preference: possible dependence on dopamine uptake blockade. Neuropsychopharmacology 26, 444 455.
47. Ronsisvalle G., Prezzavento O., Marrazzo A., Vittorio F., Massimino M., Murari G. Spampinato S. (2002) Synthesis of (+)-cis-N-(4-isothiocyanatobenzyl)- N-normetazocine, an isothiocyanate derivative of N-benzylnormetazocine as acylant agent for the σ1 receptor. J. Med. Chem. 45, 2662 2665.
48. Seth P., Fei Y. J., Li H. W., Huang W., Leibach F. H. Ganapathy V. (1998) Cloning and functional characterization of a σ receptor from rat brain. J. Neurochem. 70, 922 931.
49. Usuki E., Van der Schyf C. J. Castagnoli N. Jr. (1998) Metabolism of haloperidol and its tetrahydropyridine dehydration product HPTP. Drug Metab. Rev. 30, 809 826.
50. Usuki E., Bloomquist J. R., Freeborn E., Casagnoli K., Van der Schyf C. J. Castagnoli N. Jr. (2002) Metabolic studies on haloperidol and its tetrahydropyridinyl dehydration product (HPTP) in C57BL/6 mouse brain preparations. Neurotox. Res. 4, 51 58.